Application note: Direct and Competitive Live Cell Antibody Binding
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding
List view / Grid view
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. Life Biosciences are specifically focused on restoring and prolonging one’s…
Explore cutting-edge hit-to-lead insights through exclusive interviews and studies by leading experts in the field.
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
In this interview we discuss with Alder Therapeutics regenerative cell therapy development through a proactive strategy, addressing manufacturing challenges early and ensuring a streamlined process. We explore an approach in pluripotent stem cell therapy development which eliminates complexities, minimises costs and expedites the delivery of transformative therapies.
A new discovery about the dynamic structure of norovirus particles has implications for vaccine development.
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.